Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Design and Characterization of a Recombinant Brucella Abortus Rb51 Vaccine That Elicits Enhanced T Cell-Mediated Immune Response Publisher



Sarmadi M1 ; Gheibi A2 ; Khanahmad H1 ; Khorramizadeh MR2, 3 ; Hejazi SH4 ; Zahedi N1 ; Mianesaz H1 ; Kashfi K5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  2. 2. Department of Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences (TUMS), Tehran, 14177-55469, Iran
  3. 3. Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, 1411713139, Iran
  4. 4. Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  5. 5. Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, 10031, NY, United States
  6. 6. City University of New York Graduate Center, New York, 10016, NY, United States

Source: Vaccines Published:2022


Abstract

Brucella abortus vaccines help control bovine brucellosis. The RB51 strain is a live attenuated vaccine with low side effects compared with other live attenuated brucellosis vaccines, but it provides insufficient protective efficacy. Cell-mediated immune responses are critical in resistance against intracellular bacterial infections. Therefore, we hypothesized that the listeriolysin O (LLO) expression of Listeria monocytogenes, BAX, and SMAC apoptotic proteins in strain RB51 could enhance vaccine efficacy and safety. B. abortus RB51 was transformed separately with two broad-host-range plasmids (pbbr1ori-LLO and pBlu–mLLO-BAX-SMAC) constructed from our recent work. pbbr1ori-LLO contains LLO, and pBlu–mLLO-BAX-SMAC contains the mutant LLO and BAX-SMAC fusion gene. The murine macrophage-like cell line J774A.1 was infected with the RB51 recombinant strain containing pBlu-mLLO-BAX-SMAC, RB51 recombinant strain containing LLO, and RB51 strain. The bacterial cytotoxicity and survival and apoptosis of host cells contaminated with our two strain types—RB51 recombinants or the parental RB51—were assessed. Strain RB51 expressing mLLO and BAX-SMAC was tested in BALB/c mice and a cell line for enhanced modulation of IFN-γ production. LDH analysis showed that the RB51-mLLO-BAX-SMAC and RB51-LLO strains expressed higher cytotoxicity in J774A.1 cells than RB51. In addition, RB51 recombinants had lower macrophage survival rates and caused higher levels of apoptosis and necrosis. Mice vaccinated with the RB51 recombinant containing mLLO-BAX-SMAC showed an enhanced Th1 immune response. This enhanced immune response is primarily due to bacterial endosome escape and bacterial antigens, leading to improved apoptosis and cross-priming. This potentially enhanced TCD8 + - and T cell-mediated immunity leads to the increased safety and potency of the RB51 recombinant (RB51 mLLO-BAX-SMAC) as a vaccine candidate against B. abortus. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Related Docs
1. Development of New Generation of Vaccines for Brucella Abortus, Heliyon (2018)
2. Optimization and Comparison of Different Methods and Factors for Efficient Transformation of Brucella Abortus Rb51strain, Advanced Biomedical Research (2019)
3. Intraperitoneal Immunization With Urease Loaded N-Trimethyl Chitosan Nanoparticles Elicits High Protection Against Brucella Melitensis and Brucella Abortus Infections, Immunology Letters (2018)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Khorramizadeh (2)
Sassan Rezaie (1)